
Lecanemab Can Delay Alzheimer’s 8 Years: New Data, New Hope
New long-term data suggests lecanemab could delay the shift from mild memory loss to moderate Alzheimer’s by up to eight years—offering families precious time and renewed hope.

New long-term data suggests lecanemab could delay the shift from mild memory loss to moderate Alzheimer’s by up to eight years—offering families precious time and renewed hope.

Leqembi is one of the first Alzheimer’s treatments proven to slow decline. A new MRI study helps explain what it can—and cannot—do in the brain’s early months, offering clearer expectations for caregivers.

NEW RESEARCH: A diabetes medication already helping millions, called Jardiance, improves memory, strengthens blood flow, and supports overall brain health in pre- and early Alzheimer’s.

Some everyday medicines may nudge dementia risk higher — but safer, equally effective alternatives often exist. Here’s how to replace high-risk drugs with brain-friendlier options

IMAGINE THIS: Instead of going to an infusion center for treatment, you can switch to a weekly injection at home. That’s now a reality for many Alzheimer’s patients.

Caring for someone with Alzheimer’s is demanding enough. Now, instead of traveling for hours of infusions, families can turn to Leqembi IQLIK—a once-weekly injection approved by the FDA that makes treatment simpler, safer, and closer to home.

They’re not just pills—they’re precision infusions designed to slow Alzheimer’s at its source. See UCLA’s cutting-edge Amyloid Immunotherapy Care Program, and what it feels like to begin treatment with Leqembi (lecanemab) and Kisunla (donanemab).

Leqembi, the first Alzheimer’s-modifying drug, is a giant step forward—but how many people are getting it, and what does it really cost the average American? We dig into the numbers, the barriers, and the path forward.

FDA approves a newly recommended dosing schedule for Kisunla (Donanemab). It’s significantly safer due to lowered ARIA-E rates, which has been the main problem with these drugs.

Lecanemab (marketed as Leqembi) is today’s top Alzheimer’s drug. Why does equitable access to this drug remain a significant challenge? What needs to be done?

TEEPA SNOW explains how to handle caregiver stress that is brought on by challenging behaviors in dementias such as Alzheimer’s.

TEEPA SNOW MOTHERS’ DAY TIPS: Check out these Alzheimer’s care tips for USA’s Mothers’ Day, compiled by Dementia-specialist Teepa Snow and Senior Helpers.

In an Alzheimer’s study, insulin delivered high up in the nasal cavity achieved lasting results in improving memory. Find out why Dr. W. Banks calls this “one of those studies where everything is coming together.”

Three important dementia studies focus on HS-AGING, a type of dementia almost as common as Alzheimer’s in the 85+ group. Yet few people have heard of it. Why? What makes it different?

An intriguing study of 120 grandmothers might surprise you. Doctors know socially engaged people have better cognition and less dementia. But can a person get too much of a good thing? What’s the right balance?

Enjoy this great duet between a musician with dementia and his son. A triumph of spirit over Alzheimer’s! Sing-a-long if you like!

It looks like a sneeze cannot give anyone Alzheimer’s. While Alzheimer’s abnormal disease proteins do spread from cell-to-cell, they are not “infectious”. Check out the facts.
No spam, only news and updates.



We use cookies and similar technologies to improve your experience, understand how our content is used, and support relevant advertising that helps keep Alzheimer’s Weekly free to readers. You can choose to accept, deny, or manage your preferences at any time. Declining certain cookies may affect features such as embedded videos, comments, and personalized advertising.